Posters and Oral presentations

Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant melanoma

Modulation of immune gene expression by intra tumoral oncolytic adenovirus ONCOS 102 is associated with clinical response in anti PD 1 refractory/resistant melanoma

Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors

A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24-month survival data

"A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma"

"A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12-month analysis of biomarkers and clinical outcomes"

"Phase 1/2 Study to Evaluate Systemic Durvalumab + Intraperitoneal ONCOS-102 in Patients with Peritoneal Disease who have Epithelial Ovarian or Metastatic Colorectal Cancer: Interim Phase 1 Clinical and Translational Results"

"Next generation ONCOS oncolytic adenovirus with novel anti-cancer double-transgenes shows synergistic anti-cancer effect in a melanoma mouse model"

“Next generation ONCOS double transgene oncolytic adenovirus exhibits enhanced anti-cancer effect in pre-clinical melanoma model”

“Oncolytic Adenovirus Ad5/3-D24-GM-CSF Infects, Replicates and Lyses Ovarian Cancer Cells Through Desmoglein-2 Cell Entry Receptor”

Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model

The combinatory treatment of the oncolytic adenovirus ONCOS-102 with anti PD-1 (KEYTRUDA®) show synergistic anti-tumor effect in humanized A2058 melanoma huNOG mouse model

ONCOS-102 and Pemetrexed/cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival

An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors

Tumor-infiltrating lymphocytes (TILs) following intratumoral administration of ONCOS-102 are associated with prolonged overall survival in last line solid tumor patients

Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients

Intratumoral ONCOS-102 Shapes the Tumor Microenvironment in Last-Line Refractory Solid Tumor Patients

Characterization of tumor-infiltrating lymphocytes following intratumoral administration of ONCOS-102 for refractory solid tumor cancer patients

Induction of anti-tumor CD8+ T cells and prominent infiltration of lymphocytes with a Th1 polarizing signature to pleural mesothelioma tumor after intratumoral injection of ONCOS-102

Repeated intratumoral administration of ONCOS-102 leads to robust cellular and transcriptional immune activation at tumor site in an ovarian cancer patient